April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Short-term efficacy of single ranibizumab injection in Japanese patients with macular edema secondary to branch retinal vein occlusion; a comparison between treatment naïve cases and patients with past treatment
Author Affiliations & Notes
  • Akira Ojima
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Tetsuju Sekiryu
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Masaaki Saito
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Yasuharu Oguchi
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Masashi Ogasawara
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Ryutarou Tomita
    Ophthalmology, Fukushima Medical University, Fukushima, Japan
  • Footnotes
    Commercial Relationships Akira Ojima, None; Tetsuju Sekiryu, None; Masaaki Saito, None; Yasuharu Oguchi, None; Masashi Ogasawara, None; Ryutarou Tomita, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3866. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Akira Ojima, Tetsuju Sekiryu, Masaaki Saito, Yasuharu Oguchi, Masashi Ogasawara, Ryutarou Tomita; Short-term efficacy of single ranibizumab injection in Japanese patients with macular edema secondary to branch retinal vein occlusion; a comparison between treatment naïve cases and patients with past treatment. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3866.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the short-term efficacy of single intravitreal ranibizumab injection (IVR) in Japanese patients with macular edema secondary to branch retinal vein occlusion (BRVO).

Methods: A prospective case series. Thirty three eyes of 33 patients with macular edema secondary to BRVO were evaluated; 14 males and 19 females, mean age 73 years old. In all 33 eyes, 16 eyes were treatment naïve (naïve group) and 17 eyes had history of previous treatment (past treatment group); 4 eyes with photocoagulation (PC), 2 eyes with intravitreal bevacizumab injection (IVB), 2 eyes with sub-tenon injection of triamcinolone (STTA), 6 eyes with PC and STTA, 1 eye with PC and IVB, and 2 eyes with all of the three treatments. We performed single IVR to all 33 eyes. Best corrected visual acuity (BCVA) was measured at baseline and 1 month after IVR by using a standard Japanese Landolt visual acuity chart. At the same time, we assessed macular edema using optical coherence tomography (Spectralis OCT, Heidelberg, Germany).

Results: The mean decimal BCVA at baseline were 0.29, 0.35, and 0.24 in all patients, naïve group, and past treatment group, respectively. One month after IVR, macular edema disappeared in 19 of all 33 eyes (57.6%), 10 of 16 eyes (62.5%) in naïve group, and 9 of 17 eyes (52.9%) in past treatment group. The mean decimal BCVA improved to 0.40 (p=0.00004), 0.51 (p=0.001), and 0.33 (p=0.007) in all patients, naïve group, and past treatment group, respectively. There was no statistical difference in the mean BCVA between naïve group and past treatment group at baseline (p=0.12), whereas the mean BCVA in naïve group was significantly better than that in past treatment group 1 month after IVR (p=0.04). The BCVA was improved by one or more lines in 23 eyes (69.7%), stable in 7 eyes (21.2%), and decreased by one or more lines in 3 eyes (9.1%).

Conclusions: The single IVR could improve BCVA in the eyes with macular edema secondary to BRVO regardless of past treatment. However, treatment naïve eyes showed a good response to single IVR.

Keywords: 749 vascular occlusion/vascular occlusive disease • 748 vascular endothelial growth factor • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×